Overview

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

Status:
Terminated

Trial end date:
2019-12-11

Target enrollment:

Participant gender:

Summary

This study evaluates the safety, tolerance, pharmacokinetics (PK), and antitumor activity of ADCT-601 in patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

ADC Therapeutics S.A.